The BCL11A gene helps guide brain development, immune cell maturation, and the switch from fetal to adult hemoglobin after birth. If it does not work properly, a person may have developmental delay, speech or learning difficulties, and unusually high fetal hemoglobin levels. In medicine, this gene is important because lowering its activity in red blood cells can help people with sickle cell disease or beta thalassemia make more fetal hemoglobin.
What is a gene?
Genes are sections of DNA that hold instructions your cells use to make molecules or direct processes in the body. Some genes provide the code for producing proteins, the parts of cells that carry out much of their work. Other genes mostly help regulate when certain processes happen, where they take place, and how strongly they operate. As a whole, genes affect how the body develops and works, and they can influence how you respond to food, stress, or medications. To go further into this topic, you can read more in the LearnHub.
Overview
BCL11AGene function
What if the gene works
The BCL11A gene helps control which genes are turned on in developing blood, brain, and immune cells. It is especially important for switching from fetal hemoglobin to adult hemoglobin after birth.
Risk
What if the gene does not work
Variants in the BCL11A gene can cause developmental delay or intellectual disability, sometimes with speech or behavior differences, while also raising fetal hemoglobin levels. Milder and more severe variants can influence which features appear and how early they are noticed.
Treatment
What does that mean for your treatment
No BCL11A-specific treatment or management approach is currently established for people with a pathogenic variant in the BCL11A gene. The BCL11A gene is, however, a well-established treatment target in sickle cell disease and transfusion-dependent beta thalassemia, where editing a blood-cell control region linked to BCL11A can raise fetal hemoglobin.
Conditions associated with BCL11A
Gene function
What if the gene works
Your body uses the BCL11A gene to guide how certain cells mature and choose the right set of genes to use. This is especially important in blood-forming cells and during early brain development. A well-known part of what the BCL11A gene does in blood cells is helping the body shift from fetal hemoglobin to the adult form after birth.
The BCL11A gene acts like a gene activity manager in certain cells. It helps turn groups of genes down or off so cells can follow the right developmental plan.
In red blood cell development, the BCL11A gene helps lower fetal hemoglobin, the oxygen-carrying form mainly used before birth. This supports the usual shift toward adult hemoglobin after birth.
This gene supports the normal development of B cells, a type of white blood cell that helps make antibodies. It helps these cells mature in an orderly way as the immune system develops.
During early brain development, the BCL11A gene helps guide when certain nerve cell programs are turned on or off. This supports normal growth, organization, and connections in the developing brain.
What is a variant?
A genetic variant is a minor change in the DNA sequence of a gene. These changes are common and help shape normal human diversity, including differences in appearance, metabolism, or how the body responds to environmental influences. Many variants have no noticeable effect and are simply part of natural genetic variation. In some cases, though, a variant can change how a gene works more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the BCL11A gene can change how much protein a cell makes or how well the protein binds DNA and partner proteins to control other genes. This is how BCL11A gene variants affect protein function: milder regulatory variants may lower activity mainly in red blood cell precursors, while more severe loss of function variants can reduce activity more broadly; the amount of activity left can shape the cellular impact and, in some people, the severity of developmental features.
How variants are linked to conditions
Pathogenic variants in the BCL11A gene can cause BCL11A-related intellectual developmental disorder, also called Dias-Logan syndrome, a rare condition that often includes developmental delay, speech and learning difficulties, and sometimes seizures or short stature. Other BCL11A gene variants are linked to higher fetal hemoglobin levels and can influence how severe sickle cell disease or beta thalassemia may be. These common variants affect disease course rather than confirming a diagnosis.
A variant is not necessarily a diagnosis
Variants are a routine feature of human biology and are widely found across the population. Most do not directly affect health and instead reflect normal human variation. For many genes, having a variant associated with a condition points to a potential link, not a confirmed diagnosis, particularly when several genes and environmental influences contribute. Still, in certain situations, one well-characterized variant in a particular gene is enough to establish the diagnosis.
Are there things that can increase or change my risk?
There is not yet broadly confirmed evidence on specific everyday factors that increase or reduce health risk related to the BCL11A gene itself. In some blood conditions, changes in BCL11A can affect how severe symptoms are, but overall risk still depends on the exact gene change and the person’s wider health picture.
Inheritance of BCL11A variants
For families asking about the BCL11A gene inheritance pattern, disease causing variants are inherited in an autosomal dominant way. This means a parent with a pathogenic variant in the BCL11A gene can pass it to a child with a 50% chance in each pregnancy, regardless of the child's sex. Some people with a BCL11A related condition have a new (de novo) variant, which means it was not inherited from either parent.
What does my BCL11A result mean for my family?
For BCL11A, a disease-causing result is linked to a dominant pattern, which means close relatives such as parents, brothers, sisters, and children may also carry the same change. In families where a parent carries it, each child has a 1 in 2 chance of inheriting it. Some BCL11A changes happen new in the child and are not found in either parent, so a positive result does not always mean it came from a parent.
Genetic information
Genetic testing
How you find out about variants
Genetic testing for BCL11A variants uses a blood or saliva sample. A lab reads the DNA in the BCL11A gene to look for changes, either on its own or as part of a larger panel. Results can show whether a variant is present and help clarify whether it may be linked to a person’s condition.
When should I consider getting a genetic test?
Testing for the BCL11A gene may be considered if a child has unexplained developmental delay, speech delay, learning difficulties, or autism traits, especially with a family history of similar features. It may also be looked at when blood tests show unusually high fetal hemoglobin as part of broader genetic testing.
A genetic result is only one part of your health story
A genetic finding may offer useful information, but how much it explains depends on the condition and on the kind of variant involved. Over time, the way the body functions is shaped by many factors, including lifestyle, environment, age, and medical history. For some conditions, especially those influenced by many genes, genetic information provides context rather than certainty and is best understood together with other parts of care. In other situations, a genetic result can give a clear answer. In areas like medication response, it can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Some people break down a drug faster or slower than others, while some may be more likely to get side effects or may not get the same benefit from a treatment. These differences are common and are one reason the same medication can work well for one person but less well for another. Genetic information can sometimes help explain part of that variation, alongside age, other health conditions, and other medicines.
What is Pharmacogenetics?
Pharmacogenetics examines how genetic differences affect the way people respond to medicines. It studies connections between genes and drugs to better explain why the same treatment can work differently from one person to another. For many medications, genes influence both how strongly a drug works and how the body processes it. This information can help support treatment decisions that are more informed and more individualized. More information about this topic is available in the LearnHub.
Drugs influenced by the BCL11A gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choices, so questions about medicines, side effects, or treatment response are best discussed with your doctor. For the BCL11A gene, research has looked at whether inherited changes may affect fetal hemoglobin levels and treatment response in people living with sickle cell disease, but this is not used routinely to make medication decisions.
History
The BCL11A gene entered medical genetics through studies of blood cancers in the early 2000s, when researchers identified it in chromosome changes seen in some leukemia cases. From these first observations, research expanded steadily. Scientists later recognized that the BCL11A gene was also central to the long-standing effort to understand why babies make fetal hemoglobin before switching to adult hemoglobin after birth. That discovery became a major turning point because it linked the BCL11A gene to conditions such as sickle cell disease and beta thalassemia in a way that opened new treatment strategies. In recent years, the BCL11A gene has gained wider attention as gene-based therapies were developed to raise fetal hemoglobin by reducing its activity in blood-forming cells. Its history now spans both cancer genetics and one of the most important advances in inherited blood conditions.